Levocetirizine Hydrochloride 5mg Tablets
Formulation Overview: Third-generation non-sedating H1-receptor antagonist film-coated tablet providing 24-hour histamine blockade for rapid relief of sneezing, rhinorrhea, nasal pruritus, and chronic hives. Formulated with Levocetirizine Hydrochloride IP (5 mg) in Film-Coated Tablets dosage form under Respiratory & Allergy, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-003 |
| Therapeutic Sector | Respiratory & Allergy |
| Dosage Form | Film-Coated Tablets |
| Active Ingredient | Levocetirizine Hydrochloride IP |
| Strength / Purity | 5 mg |
| Clinical Indication | Perennial and seasonal allergic rhinitis, chronic idiopathic urticaria, and allergic conjunctivitis |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 10 x 10 Alu-Alu Blister Pack |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C, protect from moisture & direct sunlight |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |